| RS1953064795 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953064841 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953066164 |
MYO7A
|
Health Risk |
Likely pathogenic |
Usher syndrome type 1, Usher syndrome type 1 |
| RS1953066558 |
MYO7A
|
Health Risk |
Pathogenic |
— |
| RS1953067028 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953069110 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953072149 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS1953073126 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953075862 |
MYO7A
|
Health Risk |
Likely pathogenic |
Retinal dystrophy, Retinal dystrophy |
| RS1953090856 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953091771 |
C2CD3
|
Health Risk |
Likely pathogenic |
Orofaciodigital syndrome type 14, Orofaciodigital syndrome type 14 |
| RS1953092495 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953100514 |
C2CD3
|
Health Risk |
Likely pathogenic |
— |
| RS1953131447 |
MYO7A
|
Health Risk |
Pathogenic |
— |
| RS1953151412 |
MYO7A
|
Health Risk |
Pathogenic |
— |
| RS1953155445 |
GNPTAB
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953155498 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953165224 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953165554 |
GNPTAB
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953188177 |
EHMT1
|
Health Risk |
Pathogenic |
Kleefstra syndrome 1, Kleefstra syndrome 1 |
| RS1953258238 |
ST14
|
Health Risk |
Likely pathogenic |
— |
| RS1953288507 |
CEP63
|
Health Risk |
Pathogenic |
— |
| RS1953320426 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis, Mucolipidosis |
| RS1953321100 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953321606 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953326710 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953327287 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953327561 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS1953365097 |
ANKRD17
|
Health Risk |
Pathogenic |
Chopra-Amiel-Gordon syndrome, Chopra-Amiel-Gordon syndrome |
| RS1953368935 |
ST14
|
Health Risk |
Likely pathogenic |
Autosomal recessive congenital ichthyosis 11, Autosomal recessive congenital ichthyosis 11 |
| RS1953383789 |
DDB2
|
Health Risk |
Conflicting classifications of pathogenicity |
Ovarian cancer, Ovarian cancer |
| RS1953425077 |
EHMT1
|
Health Risk |
Pathogenic |
Intellectual disability, Intellectual disability |
| RS1953470546 |
PAX6
|
Health Risk |
Pathogenic |
Irido-corneo-trabecular dysgenesis, Aniridia 1 |
| RS1953476601 |
ZMYM2
|
Health Risk |
Likely pathogenic |
Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities, Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities |
| RS1953478890 |
PAX6
|
Health Risk |
Pathogenic |
Irido-corneo-trabecular dysgenesis, Aniridia 1 |
| RS1953513223 |
MYO7A
|
Health Risk |
Pathogenic |
Usher syndrome type 1B, Usher syndrome type 1 |
| RS1953513506 |
PAX6
|
Health Risk |
Pathogenic |
Aniridia 1, Irido-corneo-trabecular dysgenesis |
| RS1953519454 |
MYO7A
|
Health Risk |
Pathogenic |
Retinal dystrophy, Retinal dystrophy |
| RS1953535914 |
PAX6
|
Health Risk |
Pathogenic |
— |
| RS1953562945 |
C2CD3
|
Health Risk |
Pathogenic |
— |
| RS1953580574 |
WNK1
|
Health Risk |
Conflicting classifications of pathogenicity |
Pseudohypoaldosteronism type 2C, Neuropathy |
| RS1953583830 |
KCNJ11
|
Health Risk |
Conflicting classifications of pathogenicity |
Permanent neonatal diabetes mellitus, Maturity-onset diabetes of the young |
| RS1953589834 |
KCNJ11
|
Health Risk |
Conflicting classifications of pathogenicity |
Maturity-onset diabetes of the young, Maturity-onset diabetes of the young |
| RS1953591118 |
KCNJ11
|
Health Risk |
Conflicting classifications of pathogenicity |
Permanent neonatal diabetes mellitus, Maturity-onset diabetes of the young |
| RS1953668281 |
DDB2
|
Health Risk |
Likely pathogenic |
— |
| RS1953701770 |
ZMYND11
|
Health Risk |
Likely pathogenic |
Intellectual disability, autosomal dominant 30 |
| RS1953791177 |
ABCC8
|
Health Risk |
Conflicting classifications of pathogenicity |
Maturity-onset diabetes of the young, Transitory neonatal diabetes mellitus |
| RS1953795381 |
ABCC8
|
Health Risk |
Likely pathogenic |
— |
| RS1953843456 |
ABCC8
|
Health Risk |
Likely pathogenic |
Hereditary hyperinsulinism, Hereditary hyperinsulinism |
| RS1953845407 |
ABCC8
|
Health Risk |
Likely pathogenic |
Diabetes mellitus, permanent neonatal 3 |
| RS1953871835 |
PRIM1
|
Health Risk |
Pathogenic |
Primordial dwarfism-immunodeficiency-lipodystrophy syndrome, Seckel syndrome |
| RS1953885548 |
ABCC8
|
Health Risk |
Conflicting classifications of pathogenicity |
Transitory neonatal diabetes mellitus, Maturity-onset diabetes of the young |
| RS1953896100 |
PAX6
|
Health Risk |
Pathogenic |
Aniridia 1, Irido-corneo-trabecular dysgenesis |
| RS1953899672 |
ABCC8
|
Health Risk |
Conflicting classifications of pathogenicity |
Maturity-onset diabetes of the young, Type 2 diabetes mellitus |
| RS1953909830 |
PAX6
|
Health Risk |
Pathogenic |
— |
| RS1953942935 |
CPAP
|
Health Risk |
Pathogenic |
— |
| RS1953949496 |
CPAP
|
Health Risk |
Pathogenic |
— |
| RS1953961273 |
PAX6
|
Health Risk |
Pathogenic |
Irido-corneo-trabecular dysgenesis, Aniridia 1 |
| RS1953966878 |
WNK1
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Neuropathy |
| RS1953969921 |
PAX6
|
Health Risk |
Likely pathogenic |
— |
| RS1953981445 |
ABCC8
|
Health Risk |
Likely pathogenic |
— |
| RS1953988179 |
ABCC8
|
Health Risk |
Conflicting classifications of pathogenicity |
Transitory neonatal diabetes mellitus, Maturity-onset diabetes of the young |
| RS1954013968 |
ABCC8
|
Health Risk |
Likely pathogenic |
Hyperinsulinemic hypoglycemia, familial |
| RS1954023351 |
ATP7B
|
Health Risk |
Pathogenic/Likely pathogenic |
Wilson disease, Wilson disease |
| RS1954058406 |
ABCC8
|
Health Risk |
Conflicting classifications of pathogenicity |
Hereditary hyperinsulinism, Transitory neonatal diabetes mellitus |
| RS1954079044 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954081053 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954081372 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954082764 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954084273 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954086080 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954088614 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954091762 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954107890 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954108641 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954108778 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954187933 |
EXT2
|
Health Risk |
Likely pathogenic |
Ovarian cancer, Ovarian cancer |
| RS1954226902 |
MYO7A
|
Health Risk |
Pathogenic/Likely pathogenic |
Usher syndrome, Usher syndrome type 1 |
| RS1954237712 |
MYO7A
|
Health Risk |
Likely pathogenic |
Usher syndrome type 1, Usher syndrome type 1 |
| RS1954240719 |
MYO7A
|
Health Risk |
Pathogenic |
Usher syndrome type 2, Usher syndrome type 2 |
| RS1954248090 |
MYO7A
|
Health Risk |
Pathogenic/Likely pathogenic |
Usher syndrome type 1, Usher syndrome type 1 |
| RS1954250327 |
MYO7A
|
Health Risk |
Likely pathogenic |
Usher syndrome type 1, Usher syndrome type 1 |
| RS1954260410 |
DIABLO
|
Health Risk |
Likely pathogenic |
Autosomal dominant nonsyndromic hearing loss 64, Autosomal dominant nonsyndromic hearing loss 64 |
| RS1954336215 |
DHX37
|
Health Risk |
Likely pathogenic |
46, XY sex reversal 11 |
| RS1954336272 |
DHX37
|
Health Risk |
Likely pathogenic |
46, XY sex reversal 11 |
| RS1954346640 |
DHX37
|
Health Risk |
Pathogenic |
46, XY sex reversal 11 |
| RS1954358233 |
DES
|
Health Risk |
Pathogenic/Likely pathogenic |
Desmin-related myofibrillar myopathy, Desmin-related myofibrillar myopathy |
| RS1954359599 |
DES
|
Health Risk |
Conflicting classifications of pathogenicity |
Desmin-related myofibrillar myopathy, Cardiovascular phenotype |
| RS1954365477 |
DES
|
Health Risk |
Pathogenic/Likely pathogenic |
Desmin-related myofibrillar myopathy, Desmin-related myofibrillar myopathy |
| RS1954372352 |
DES
|
Health Risk |
Pathogenic |
Desmin-related myofibrillar myopathy, Desmin-related myofibrillar myopathy |
| RS1954372994 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954373010 |
DES
|
Health Risk |
Likely pathogenic |
Desmin-related myofibrillar myopathy, Desmin-related myofibrillar myopathy |
| RS1954373394 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954373441 |
DES
|
Health Risk |
Conflicting classifications of pathogenicity |
Desmin-related myofibrillar myopathy, Desmin-related myofibrillar myopathy |
| RS1954374127 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954374671 |
DES
|
Health Risk |
Pathogenic/Likely pathogenic |
DES-related disorder, Desmin-related myofibrillar myopathy |
| RS1954375189 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954378294 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954411419 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |
| RS1954411719 |
EXT2
|
Health Risk |
Pathogenic |
Exostoses, multiple |